Addenda Capital Inc. Buys New Stake in Henry Schein, Inc. (HSIC)

Addenda Capital Inc. bought a new stake in Henry Schein, Inc. (NASDAQ:HSIC) in the fourth quarter, Holdings Channel reports. The institutional investor bought 6,917 shares of the company’s stock, valued at approximately $410,000.

A number of other institutional investors have also recently modified their holdings of the stock. Vanguard Group Inc. increased its position in Henry Schein by 3.0% in the 2nd quarter. Vanguard Group Inc. now owns 8,086,317 shares of the company’s stock valued at $1,479,959,000 after buying an additional 236,862 shares in the last quarter. FMR LLC increased its position in Henry Schein by 0.4% in the 2nd quarter. FMR LLC now owns 6,921,367 shares of the company’s stock valued at $1,266,749,000 after buying an additional 24,935 shares in the last quarter. BlackRock Inc. increased its position in Henry Schein by 1.8% in the 2nd quarter. BlackRock Inc. now owns 5,696,685 shares of the company’s stock valued at $1,042,607,000 after buying an additional 101,406 shares in the last quarter. Alecta Pensionsforsakring Omsesidigt increased its position in Henry Schein by 112.0% in the 3rd quarter. Alecta Pensionsforsakring Omsesidigt now owns 5,313,980 shares of the company’s stock valued at $435,693,000 after buying an additional 2,806,990 shares in the last quarter. Finally, Mackenzie Financial Corp increased its position in Henry Schein by 106.0% in the 3rd quarter. Mackenzie Financial Corp now owns 3,938,233 shares of the company’s stock valued at $322,896,000 after buying an additional 2,026,867 shares in the last quarter. 91.69% of the stock is owned by institutional investors and hedge funds.

In other news, Director Barry J. Alperin sold 5,796 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $70.76, for a total value of $410,124.96. Following the transaction, the director now owns 48,172 shares in the company, valued at approximately $3,408,650.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.19% of the stock is owned by insiders.

A number of brokerages recently commented on HSIC. Zacks Investment Research raised Henry Schein from a “sell” rating to a “hold” rating in a research report on Thursday, January 4th. Royal Bank of Canada decreased their target price on Henry Schein from $91.00 to $82.00 and set a “sector perform” rating for the company in a research report on Tuesday, November 7th. Jefferies Group reaffirmed a “hold” rating and issued a $89.00 target price on shares of Henry Schein in a research report on Friday, October 20th. Stephens began coverage on Henry Schein in a report on Tuesday, November 28th. They set an “equal weight” rating and a $76.00 price objective for the company. Finally, Morgan Stanley lowered Henry Schein from an “equal weight” rating to an “underweight” rating and set a $88.00 price objective for the company. in a report on Wednesday, December 6th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $84.23.

Shares of Henry Schein, Inc. (NASDAQ HSIC) opened at $74.84 on Friday. Henry Schein, Inc. has a twelve month low of $65.28 and a twelve month high of $93.50. The company has a market capitalization of $11,504.76, a P/E ratio of 20.56, a price-to-earnings-growth ratio of 1.88 and a beta of 1.00. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.86 and a current ratio of 1.55.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Monday, November 6th. The company reported $0.87 earnings per share for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). Henry Schein had a return on equity of 19.71% and a net margin of 4.52%. The business had revenue of $3.16 billion during the quarter, compared to analysts’ expectations of $3.05 billion. During the same quarter in the previous year, the firm earned $0.84 EPS. Henry Schein’s quarterly revenue was up 10.3% on a year-over-year basis. sell-side analysts predict that Henry Schein, Inc. will post 3.6 earnings per share for the current fiscal year.

Henry Schein declared that its Board of Directors has authorized a share repurchase program on Monday, September 18th that allows the company to repurchase $400.00 million in outstanding shares. This repurchase authorization allows the company to reacquire up to 6.3% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s leadership believes its shares are undervalued.

WARNING: “Addenda Capital Inc. Buys New Stake in Henry Schein, Inc. (HSIC)” was originally reported by Markets Daily and is the property of of Markets Daily. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.themarketsdaily.com/2018/01/13/addenda-capital-inc-buys-new-stake-in-henry-schein-inc-hsic.html.

Henry Schein Company Profile

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC).

Institutional Ownership by Quarter for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply